Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Immunodiagnostic Sys (IDH)

  Print      Mail a friend

Monday 11 February, 2013

Immunodiagnostic Sys

Collaboration with Diagnostica Stago

RNS Number : 5599X
Immunodiagnostic Systems Hldgs PLC
11 February 2013

11 February  2013


Immunodiagnostic Systems Holdings plc


IDS and Diagnostica Stago to Collaborate in the Field of Coagulation and Haemostasis


Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, is today pleased to announce a significant collaboration with Diagnostica Stago ("Stago"), a leading French based producer of coagulation and haemostasis diagnostic kits and instrumentation. 


Following a successful feasibility project, IDS and Stago have established a collaboration partnership to assist Stago in developing coagulation and haemostasis assays for use on the IDS-iSYS immunoanalyzer.  As part of this collaboration Stago has also agreed to help fund IDS' development of the IDS-iSYS mark II instrument and eventually deploy it in their fields of expertise.


Under the terms of the collaboration, Stago will pay IDS €3.5m in a series of milestone payments and also contribute €1m to the development of the IDS-iSYS mark II.  Both activities are expected to conclude over the next 2-3 years.  In addition, IDS expects to earn revenues from the sale of instruments, ancillary products and royalties. 


Under the terms of a pre-existing agreement dated 31 March 2005 between Alain Rousseau and Biocode Hycel (acquired by IDS in 2007), Mr. Rousseau, Engineering Director of IDS PLC and co-owner of the intellectual property rights of the IDS-iSYS, is entitled to 30% (equating to, in total, EUR1.05m) of the milestone payments to be paid by Stago to IDS relating to the licensing of the instrument technology.  Payments to Mr. Rousseau will only be made when funds are received by IDS.  With the exception of Mr. Rousseau who is deemed a related party, the Board of IDS, having consulted with Peel Hunt LLP, considers that the terms of any payments to be made to Mr. Rousseau are fair and reasonable in so far as its shareholders are concerned.


Patrik Dahlen, CEO of IDS, said: "Our collaboration with Stago reinforces our belief that the IDS-iSYS platform is one of the leading technologies in the field of specialty diagnostics.  Stago is an excellent company with a great reputation in its areas of expertise and shares IDS' values of delivering high quality tests to the specialty IVD market.  We look forward to working with Stago in the development of our respective next generation instrumentation platforms."


Bertrand Bonnot, COO of Stago, said: "This collaboration agreement is an important milestone for our company whereby accessing the new technology developed by IDS will help us to develop further our offer for high performance and high quality specialty tests supporting our commercial positions in the highly demanding field of coagulation and haemostasis."


For further information:


Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Patrik Dahlen, Chief Executive Officer




Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel


Dr Vijay Barathan




FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell


Simon Conway


Mo Noonan




About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies. 



About Stago

Stago, created in 1945, is an IVD company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Stago products are available in more than 100 countries in the world. In 2012, Stago Group had over 2,000 employees worldwide. 



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t